author-photo

Noboru Takata

Kanazawa University

9

Papers

155

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Sodium-Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized, Open-Label Trial Study

2021 Social Science Research Network
Show All
- Source
- Cite
- Save
Citations (0)
LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophages in NASH.

2021 Scientific Reports
Show All
- Source
- Cite
- Save
Citations (6)
Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma.

2020 Hepatology Research
Show All
- Source
- Cite
- Save
Citations (14)
Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma.

2020 Hepatology Research
Show All
- Source
- Cite
- Save
Citations (2)
Study Protocol for Pleiotropic Effects and Safety of Sodium–Glucose Cotransporter 2 Inhibitor Versus Sulfonylurea in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

2020 Diabetes Therapy
Show All
- Source
- Cite
- Save
Citations (1)
Hepatic arterial infusion chemotherapy after sorafenib treatment in patients with advanced hepatocellular carcinoma who are unfit for regorafenib.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Rapid response of the steatosis-sensing hepatokine LECT2 during diet-induced weight cycling in mice.

2016 Biochemical and Biophysical Research Communications
Show All
- Source
- Cite
- Save
Citations (15)
Post‐progression survival and progression‐free survival in patients with advanced hepatocellular carcinoma treated by sorafenib

2016 Hepatology Research
Show All
- Source
- Cite
- Save
Citations (41)
LECT2 functions as a hepatokine that links obesity to skeletal muscle insulin resistance

2014 Diabetes
Show All
- Source
- Cite
- Save
Citations (75)